About the Company
Precision BioSciences, Inc. is a publicly traded American clinical stage gene editing company headquartered in Durham, North Carolina. Founded in 2006, Precision is focused on developing both in vivo and ex vivo gene editing therapies using its proprietary "ARCUS" genome editing platform.
Exchange
NYSE
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $RCUS News
Arcus Biosciences to Present New Data from Phase 2 Studies of Novel Immuno-Oncology Combinations at the 2024 ASCO Annual Meeting
Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced ...
Arcus Biosciences Announces New Employment Inducement Grants
HAYWARD, Calif., April 09, 2024--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and ...
Arcus Biosciences to Host Conference Call to Discuss First-Quarter 2024 Financial Results and Pipeline Update
About Arcus Biosciences. Arcus Biosciences is a clinical-stage, global biopharmaceutical company developing differentiated molecules and combination medicines for people with canc ...
Zimberelimab by Arcus Biosciences for Metastatic Castration-Resistant Prostate Cancer (mCRPC): Likelihood of Approval
Zimberelimab is under clinical development by Arcus Biosciences and currently in Phase II for Metastatic Castration-Resistant Prostate Cancer (mCRPC).
Precision BioSciences (DTIL) Price Target Decreased by 22.17% to 36.52
The average one-year price target for Precision BioSciences (NasdaqCM:DTIL) has been revised to 36.52 / share. This is an ...
Arcus Biosciences Inc RCUS
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Arcus Biosciences Announces New Employment Inducement Grants
Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today ...
Arcus Biosciences Inc (RCUS)
Arcus Biosciences, Inc.'s (NYSE:RCUS) Chief Operating Officer, Jennifer Jarrett, has sold a total of 11,551 shares of the company's common stock, according to a recent filing with ...
Arcus Biosciences Announces New Employment Inducement Grants
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for ...
Loading the latest forecasts...